BACKGROUND: Pretreatment cytogenetics are not routinely used to predict patient outcomes in mantle cell lymphoma (MCL). Based on the prognostic utility of cytogenetics in other diseases, we reviewed the effect of a complex karyotype (CK) in MCL. PATIENTS AND METHODS: We included patients evaluated between November, 2002, and May, 2011. Those with ≥ 3 chromosomal abnormalities on a pre-treatment cytogenetic evaluation were defined as CK. Demographic, clinical, and survival differences between patients with CK and non-CK (NCK) were assessed. RESULTS: Of 80 patients, 32 (40%) had CK, which was associated with high-risk clinical risk factors. Therapy did not differ between the groups, nor did rate of autologous stem cell transplant (ASCT). The 2-year progression-free survival (PFS) estimates were 70% and 48% for patients with NCK and CK, respectively (P = .02). Two-year overall survival (OS) estimates were also greater in those with NCK versus CK (85% vs. 58%; P = .02). When controlling for high-risk Mantle Cell Lymphoma International Prognostic Index (MIPI) score (P = .006), bulky disease (P = .01), and ASCT in first remission (P = .01), CK was not significantly associated with PFS (P = .18). CONCLUSION: CK is associated with shortened PFS and OS in MCL but has not been demonstrated to be prognostic independent of other variables in this series.
BACKGROUND: Pretreatment cytogenetics are not routinely used to predict patient outcomes in mantle cell lymphoma (MCL). Based on the prognostic utility of cytogenetics in other diseases, we reviewed the effect of a complex karyotype (CK) in MCL. PATIENTS AND METHODS: We included patients evaluated between November, 2002, and May, 2011. Those with ≥ 3 chromosomal abnormalities on a pre-treatment cytogenetic evaluation were defined as CK. Demographic, clinical, and survival differences between patients with CK and non-CK (NCK) were assessed. RESULTS: Of 80 patients, 32 (40%) had CK, which was associated with high-risk clinical risk factors. Therapy did not differ between the groups, nor did rate of autologous stem cell transplant (ASCT). The 2-year progression-free survival (PFS) estimates were 70% and 48% for patients with NCK and CK, respectively (P = .02). Two-year overall survival (OS) estimates were also greater in those with NCK versus CK (85% vs. 58%; P = .02). When controlling for high-risk Mantle Cell Lymphoma International Prognostic Index (MIPI) score (P = .006), bulky disease (P = .01), and ASCT in first remission (P = .01), CK was not significantly associated with PFS (P = .18). CONCLUSION: CK is associated with shortened PFS and OS in MCL but has not been demonstrated to be prognostic independent of other variables in this series.
Authors: I Brian Greenwell; Ashley D Staton; Michael J Lee; Jeffrey M Switchenko; Debra F Saxe; Joseph J Maly; Kristie A Blum; Natalie S Grover; Stephanie P Mathews; Max J Gordon; Alexey V Danilov; Narendranath Epperla; Timothy S Fenske; Mehdi Hamadani; Steven I Park; Christopher R Flowers; Jonathon B Cohen Journal: Cancer Date: 2018-03-26 Impact factor: 6.860
Authors: Oscar Calzada; Jeffrey M Switchenko; Joseph J Maly; Kristie A Blum; Natalie Grover; Stephanie Mathews; Steven I Park; Max Gordon; Alexey Danilov; Narendranath Epperla; Timothy S Fenske; Mehdi Hamadani; Christopher R Flowers; Jonathon B Cohen Journal: Leuk Lymphoma Date: 2018-06-18